IP Library Granted Patent US 6,992,090
Granted Patent B2
US 6,992,090 · App. 10/462,507 · Granted Jan 31, 2006

Substituted piperidine compounds and methods of their use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,992,090
App. No.
10/462,507
Granted
Jan 31, 2006
Kind
B2
Abstract

Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.

Claims (67)

1. A compound of formula I:

wherein:

R 1 is H or alkyl;

R 2a is alkyl or alkenyl;

R 2b is H, alkyl or alkenyl;

R 3 is H, alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, or aralkyl;

R 4 is:

H,

aryl (optionally substituted by one or more substituents selected from —OH, nitro, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, —N(R 6a )(R 6b ), alkoxycarbonyl, aryloxy, aryl, alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms)),

aralkyl,

alkyl,

alkenyl, or

alkynyl,

which latter three groups are optionally substituted by one or more substituents selected from —OR 6c , —S(═O) q R 6d , —CN, halo, alkoxycarbonyl, —N(R 6a )(R 6b ), alkanoyl, alkanoyloxy, cycloalkyl, cycloalkanoyl, —N(R 6e )S(═O) 2 R 7a , —P(═O)OR 7b OR 7c , Het 1 , and aryl (which latter group is optionally substituted by one or more substituents selected from —OH, nitro, —N(R 6a )(R 6b ), halo, —CN, —CH 2 CN, —C(═O)NH 2 , CO 2 H, —CHO, aryl, alkyl, alkoxy, aralkoxy, aryloxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms));

R 6a , R 6b , R 6c , R 6d , and R 6e , are each independently H, Het 2 , alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or aryl (which latter six groups are optionally substituted by one or more substituents selected from OH, nitro, halo, —NHC(═O)R 3 , —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, alkoxycarbonyl, alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms));

R 5 is —(CH 2 ) y (CHR 8 ) j (CHR 8a ) z W;

R 8 is each independently aryl (optionally substituted by one or more substituents selected from —OH, nitro, aryl, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, —N(R 6a )(R 6b ), alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms)), cycloalkyl, alkyl, alkenyl or alkynyl wherein said alkyl, alkenyl or alkynyl groups are optionally substituted by one or more substituents selected from —OR 6c , —S(O) q R 6d , —CN, halo, —N(R 6a )(R 6b ), —CO 2 H, —C(═O)NH 2 , alkoxycarbonyl, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkanoyl, —N(R 6e )S(═O) 2 R 7a , —P(═O)OR 7b OR 7c , Het 1 , and aryl (which latter group is optionally substituted by one or more substituents selected from —OH, nitro, amino, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, aroyl, aryl, alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms));

R 8a is each independently H, aryl (optionally substituted by one or more substituents selected from —OH, nitro, aryl, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, —N(R 6a )(R 6b ), alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms)), cycloalkyl, alkyl, alkenyl or alkynyl wherein said alkyl, alkenyl or alkynyl groups are optionally substituted by one or more substituents selected from —OR 6c , —S(O) q R 6d , —CN, halo, amino, —CO 2 H, —C(═O)NH 2 , alkoxycarbonyl, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkanoyl, —N(R 6e )S(═O) 2 R 7a , —P(═O)OR 7b OR 7c , Het 1 , and aryl (which latter group is optionally substituted by one or more substituents selected from —OH, nitro, amino, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, aroyl, aryl, alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms));

W is —C(═O)OR 9 , —C(═O)N(R 10a )(R 10b ), or —P(═O)OR 7b OR 7c ;

R 9 is H, alkyl, alkenyl, phenyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, or aralkyl;

R 10a and R 10b , each independently represent H, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, Het 3 , or aryl (which latter seven groups are optionally substituted by one or more substituents selected from —OH, nitro, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms)); or R 10a and R 10b when taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally fused to an aromatic ring, and wherein said heterocycloalkyl ring, or the aromatic ring to which it is optionally fused, is each independently optionally substituted by one or more substituents selected from —OH, alkyl, or alkoxy; and wherein the heterocycloalkyl ring is also optionally interrupted by one or more O, S or N(R 12 ) groups;

R 7a , R 7b , R 7c , and R 7d , are each independently H, alkyl, cycloalkyl, alkaryl, aralkyl or aryl, which latter five groups are optionally substituted by one or more substituents selected from alkyl, alkoxy, —OH, nitro, amino and halo;

Het 1 , Het 2 and Het 3 each independently represent a 3- to 8-membered heterocyclic ring, wherein said heterocyclic ring contains at least one heteroatom selected from oxygen, sulfur, nitrogen or combinations thereof, wherein said heterocyclic ring is optionally fused to an aromatic ring, and wherein said heterocyclic ring, or the aromatic ring to which it is optionally fused, is each independently optionally substituted by one or more substituents selected from —OH, ═O, nitro, amino, halo, —CN, —CO 2 H, aryl, alkyl, alkoxy and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms);

R 11 represents H, alkyl, cycloalkyl, cycloalkylalkyl, or aralkyl;

R 12 represents H, alkyl, cycloalkyl, cycloalkylalkyl, or aralkyl;

j is the integer 0, 1, 2, 3, or 4;

m is the integer 0, 1, 2, 3, or 4;

q is the integer 0, 1, or 2;

y is the integer 0, 1, 2, 3, 4, or 5; and

z is the integer 0, 1, 2, 3, or 4;

with the provisos that:

when j and z are each the integer 0, y must be the integer 5; and

when R 8a is H and i is 0, the sum of y+z must be the integer 5;

or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, N-oxide or isomorphic crystalline form thereof.

2. A compound according to claim 1 , wherein R 1 is H.

3. A compound according to claim 1 , wherein R 2a and R 2b are trans to each other.

4. A compound according to claim 1 , of formula II:

5. A compound according to claim 1 , wherein R 2a and R 2b are each methyl.

6. A compound according to claim 1 , of formula III:

wherein:

R 3 is H, alkyl, or aralkyl.

7. A compound according to claim 1 , of formula IV:

wherein:

R 3 is H, alkyl, or aralkyl.

8. A compound according to claim 7 , wherein R 4 is H.

9. A compound according to claim 7 , wherein R 3 is:

10. A compound according to claim 7 , of formula V:

11. A compound according to claim 10 , wherein R 4 is H.

12. A compound according to claim 10 , of formula VIa:

13. A compound according to claim 10 , of formula VIb:

14. A compound according to claim 12 or claim 13 , wherein W is —CO 2 H, and R 2a and R 2b are each methyl.

15. A compound according to claim 12 or claim 13 , wherein R 8 is alkyl substituted with aryl, optionally substituted by one or more substituents selected from —OH, nitro, amino, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, aroyl, aryl, —N(R 6a )(R 6b ), alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms).

16. A compound according to claim 15 , wherein R 8 is optionally substituted benzyl.

17. A compound according to claim 16 , wherein said benzyl is substituted by one or more substituents selected from —OH, nitro, halo, aroyl, or aryl.

18. A compound according to claim 12 or claim 13 , wherein R 3 is:

19. A compound according to claim 1 , wherein W is —CO 2 H.

20. A compound according to claim 1 , wherein R 4 is benzyl.

21. A compound according to claim 1 , wherein R 4 is H.

22. A compound according to claim 1 , wherein m is the integer 1.

23. A compound according to claim 1 , wherein R 4 is benzyl and m is the integer 1.

24. A compound according to claim 1 , wherein R 4 is benzyl, m is the integer 1, and W is —CO 2 H.

25. A compound according to claim 1 , wherein R 3 is H, m is the integer 1, and R 4 is aryl (optionally substituted by one or more substituents selected from —OH, nitro, halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, —N(R 6a )(R 6b ), alkoxycarbonyl, aryloxy, aryl, alkyl, alkoxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms)), alkyl, alkenyl, or alkynyl, which latter three groups are optionally substituted by one or more substituents selected from —OR 6c , —S(═O) q R 6d , —CN, halo, alkoxycarbonyl, amino, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkanoyl, —N(R 6e )S(═O)2R 7a , P(═O)OR 7b OR 7c , Het 1 , and aryl (which latter group is optionally substituted by one or more substituents selected from —OH, nitro, N(R 6a )(R 6b ), halo, —CN, —CH 2 CN, —C(═O)NH 2 , —CO 2 H, —CHO, aryl, alkyl, alkoxy, aralkoxy, aryloxy, and alkanoyl (which latter three groups are optionally substituted by one or more halo atoms)).

26. A pharmaceutical composition, comprising:

a pharmaceutically acceptable carrier; and

an effective amount of a compound according to claim 1 .

27. A method for preventing or treating ileus, comprising the step of:

administering to a patient in need of such treatment, a composition comprising an effective amount of a compound according to claim 1 .

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNOR FILED ON OCT. 30, 2003, RECORDED AT REEL 014633 FRAME 0144. THE ASSIGNOR HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST. Recorded Jul 27, 2004
From: BOURDONNEC, BERTRAND LE; DOLLE, ROLAND E.
To: ADOLOR CORPORATION
Reel/Frame 014956/0742 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2003
From: LE BOURDONNEC, BERTRAND; DOLLE, ROLAND E.
To: ADOLOR CORPORATION
Reel/Frame 014633/0144 →